New insights into the neurobiological mechanisms of major depressive disorders

General Hospital Psychiatry

Volumn 37, Issue 2, 2015, Pages 172-177

  Fakhoury, Marc ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Antidepressant drug; Major depressive disorder; Neurobiology; Neurotransmitter

Indexed keywords

ADRENALIN; ANTIDEPRESSANT AGENT; DOPAMINE; MONOAMINE OXIDASE INHIBITOR; NEUROTROPHIC FACTOR; RESERPINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AMYGDALOID NUCLEUS; ARTICLE; BASAL GANGLION; BODY WEIGHT DISORDER; BRAIN DEPTH STIMULATION; BRAIN SIZE; CARDIOVASCULAR DISEASE; DIZZINESS; DROWSINESS; ELECTROCONVULSIVE THERAPY; ENVIRONMENTAL FACTOR; EPIGENETICS; FORCED SWIM TEST; GENERALIZED ANXIETY DISORDER; GENETIC RISK; GENOTYPE ENVIRONMENT INTERACTION; HEADACHE; HIPPOCAMPUS; HUMAN; HYPERTENSION; INSOMNIA; MAJOR DEPRESSION; MENTAL DISEASE; NEUROBIOLOGY; NEUROIMAGING; NONHUMAN; OLFACTORY BULBECTOMY; PATHOPHYSIOLOGY; SEDATION; SEIZURE; SEROTONIN BRAIN LEVEL; SEROTONIN SYNDROME; SOCIAL PHOBIA; SUICIDAL IDEATION; TREATMENT RESISTANT DEPRESSION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WOUND INFECTION; ANIMAL; DEPRESSIVE DISORDER, MAJOR; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; DEPRESSIVE DISORDER, MAJOR; HUMANS;

EID: 84924805077     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2015.01.005     Document Type: Article

References (76)

1. Weissman M.M., Boyd J.D. The epidemiology of affective disorders. Neurobiology of Mood Disorders 1984, Williams and Wilkins, Baltimore.
2. Kenneson A., Funderburk J.S., Maisto S.A. Substance use disorders increase the odds of subsequent mood disorders. Drug Alcohol Depend 2013, 133(2):338-343.
3. Konarski J.Z., McIntyre R.S., Grupp L.A., Kennedy S.H. Is the cerebellum relevant in the circuitry of neuropsychiatric disorders?. J Psychiatry Neurosci 2005, 30(3):178-186.
4. Schmahmann J.D., Weilburg J.B., Sherman J.C. The neuropsychiatry of the cerebellum - insights from the clinic. Cerebellum 2007, 6(3):254-267.
5. Nutt D.J. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry 2008, 69(1):4-7.
6. Villanueva R. Neurobiology of major depressive disorder. Neural Plast 2013, 2013:873278.
7. Delgado P.L., Schillerstrom J. Cognitive difficulties associated with depression: what are the implications for treatment?. Psychiatr Times 2009, 26(3).
8. André C., Dinel A.L., Ferreira G., Layé S., Castanon N. Diet-induced obesity progressively alters cognition, anxiety-like behavior and lipopolysaccharide-induced depressive-like behavior: focus on brain indoleamine 2, 3-dioxygenase activation. Brain Behav Immun 2014, 41:10-21.
9. Cizza G., Marques A.H., Eskandari F., Christie I.C., Torvik S., Silverman M.N., et al. Elevated neuroimmune biomarkers in sweat patches and plasma of premenopausal women with major depressive disorder in remission: the POWER study. Biol Psychiatry 2008, 64(10):907-911.
10. Korhonen T., Loukola A., Wedenoja J., Nyman E., Latvala A., Broms U., et al. Role of nicotine dependence in the association between the dopamine receptor gene DRD3 and major depressive disorder. PLoS One 2014, 9(6):e98199.
11. Chang Y.H., Chen S.L., Lee S.Y., Hsu Y.W., Wu J.Y., Chen S.H., et al. Neuropsychological functions in bipolar disorders I and II with and without comorbid alcohol dependence. Prog Neuropsychopharmacol Biol Psychiatry 2012, 37(2):211-216.
12. Nemeroff C.B. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psychiatr Res 2007, 41(3-4):189-206.
13. Maletic V., Robinson M., Oakes T., Iyengar S., Ball S.G., Russell J. Neurobiology of depression: an integrated view of key findings. Int J Clin Pract 2007, 61(12):2030-2040.
14. Lohoff F.W. Overview of the genetics of major depressive disorder. Curr Psychiatry Rep 2010, 12(6):539-546.
15. Abkevich V., Camp N.J., Hensel C.H., Neff C.D., Russell D.L., Hughes D.C., et al. Predisposition locus for major depression at chromosome 12q22-12q23.2. Am J Hum Genet 2003, 73(6):1271-1281.
16. Candidate genes for depression" [Accessed on August 22, 2014]. http://www.dnalc.org/view/1464-Candidate-Genes-for-Depression.html.
17. Coppen A. The biochemistry of affective disorders. Br J Psychiatry 1967, 113(504):1237-1264.
18. Menke A., Klengel T., Rubel J., Brückl T., Pfister H., Lucae S., et al. Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. Genes Brain Behav 2013, 12(3):289-296.
19. Castrén E., Võikar V., Rantamäki T. Role of neurotrophic factors in depression. Curr Opin Pharmacol 2007, 7(1):18-21.
20. Molendijk M.L., Bus B.A., Spinhoven P., Penninx B.W., Kenis G., Prickaerts J., et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2011, 16(11):1088-1095.
21. Cattaneo A., Gennarelli M., Uher R., Breen G., Farmer A., Aitchison K.J., et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology 2013, 38(3):377-385.
22. Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, Ripke S., Wray N.R., Lewis C.M., Hamilton S.P., Weissman M.M. A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry 2013, 18(4):497-511.
23. Breslau N., Davis G.C. Chronic stress and major depression. Arch Gen Psychiatry 1986, 43(4):309-314.
24. Kendler K.S., Kuhn J.W., Vittum J., Prescott C.A., Riley B. The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch Gen Psychiatry 2005, 62(5):529-535.
25. Lok A., Bockting C.L., Koeter M.W., Snieder H., Assies J., Mocking R.J., et al. Interaction between the MTHFR C677T polymorphism and traumatic childhood events predicts depression. Transl Psychiatry 2013, 3:e288.
26. Ikegame T., Bundo M., Murata Y., Kasai K., Kato T., Iwamoto K. DNA methylation of the BDNF gene and its relevance to psychiatric disorders. J Hum Genet 2013, 58(7):434-438.
27. Li E., Bestor T.H., Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992, 69(6):915-926.
28. Cooney C.A., Dave A.A., Wolff G.L. Maternal methyl supplements in mice affect epigenetic variation and DNA methylation of offspring. J Nutr 2002, 132(8 Suppl.):2393S-2400S.
29. Szczepankiewicz A., Leszczyńska-Rodziewicz A., Pawlak J., Rajewska-Rager A., Wilkosc M., Zaremba D., et al. Epistatic interaction between CRHR1 and AVPR1b variants as a predictor of major depressive disorder. Psychiatr Genet 2013, 23(6):239-246.
30. Ahdidan J., Foldager L., Rosenberg R., Rodell A., Videbech P., Mors O. Hippocampal volume and serotonin transporter polymorphism in major depressive disorder. Acta Neuropsychiatry 2013, 25(4):206-214.
31. Marchand W.R., Dilda V., Jensen C.R. Neurobiology of mood disorders. Hosp Physician 2005, 41(9):17-26.
32. Mayberg H. Brain pathway may underlie depression. Sci Am 2007, 17(4):26-31.
33. Rosso I.M., Cintron C.M., Steingard R.J., Renshaw P.F., Young A.D., Yurgelun-Todd D.A. Amygdala and hippoccampus volumes in pediatric major depression. Biol Psychiatry 2005, 57:21-26.
34. Swanson L.W. The hypothalamus. Handbook of Chemical Neuroanatomy 1987, vol. 5. Elsevier, New York, NY. A. Björklund (Ed.).
35. Kempton M.J., Salvador Z., Munafò M.R., Geddes J.R., Simmons A., Frangou S., et al. Structural neuroimaging studies in major depressive disorder: meta-analysis and comparison with bipolar disorder. Arch Gen Psychiatry 2011, 68(7):675-690.
36. Soares J.C., Mann J.J. The functional neuroanatomy of mood disorders. J Psychiatr Res 1997, 31(4):393-432.
37. Lemogne C., Delaveau P., Freton M., Guionnet S., Fossati P. Medial prefrontal cortex and the self in major depression. J Affect Disord 2012, 136(1-2):e1-e11.
38. Heimer L. A new anatomical framework for neuropsychiatric disorders and drug abuse. Am J Psychiatry 2003, 160(10):1726-1739.
39. Leech R., Sharp D.J. The role of the posterior cingulate cortex in cognition and disease. Brain 2014, 137(Pt 1):12-32.
40. Hatton S.N., Lagopoulos J., Hermens D.F., Naismith S.L., Bennett M.R., Hickie I.B. Correlating anterior insula gray matter volume changes in young people with clinical and neurocognitive outcomes: an MRI study. BMC Psychiatry 2012, 12:45.
41. Lorenzetti V., Allen N.B., Fornito A., Yücel M. Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies. J Affect Disord 2009, 117(1-2):1-17.
42. Galani V.J., Rana D.G. Depression and antidepressants with dopamine hypothesis - a review. IJPFR 2011, 1(2):45-60.
43. Benkert O., Renz A., Marano C., Matussek N. Altered tyrosine daytime plasma levels in endogenous depressive patients. Arch Gen Psychiatry 1971, 25(4):359-363.
44. Antkiewicz-Michaluk L., Wąsik A., Moz˙dz˙eń E., Romańska I., Michaluk J. Antidepressant-like effect of tetrahydroisoquinoline amines in the animal model of depressive disorder induced by repeated administration of a low dose of reserpine: behavioral and neurochemical studies in the rat. Neurotox Res 2014, 26(1):85-98.
45. Lepola U., Arató M., Zhu Y., Austin C. Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. J Clin Psychiatry 2003, 64(6):654-662.
46. Delini-Stula A., Mikkelsen H., Angst J. Therapeutic efficacy of antidepressants in agitated anxious depression - a meta-analysis of moclobemide studies. J Affect Disord 1995, 35(1-2):21-30.
47. Vaswani M., Linda F.K., Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27(1):85-102.
48. Tan T.X. Major depression in China-to-US immigrants and US-born Chinese Americans: testing a hypothesis from culture-gene co-evolutionary theory of mental disorders. J Affect Disord 2014, 167:30-36.
49. Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Psychiatric Press, Inc., Washington, DC. 4th ed. revised.
50. Sanacora G., Mason G.F., Rothman D.L., Behar K.L., Hyder F., Petroff O.A., et al. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 1999, 56(11):1043-1047.
51. Forbes E.E. fMRI studies of reward processing in adolescent depression. Neuropsychopharmacology 2011, 36:372-373.
52. Schena A., Ansseau M., Triffaux J.M., Salmon E., Withofs N., Scantamburlo G. Clinical study of the month: depressive pseudo-dementia. Rev Med Liege 2014, 69(2):64-67.
53. Zhang J., Wang J., Wu Q., Kuang W., Huang X., He Y., et al. Disrupted brain connectivity networks in drug-naive, first-episode major depressive disorder. Biol Psychiatry 2011, 70(4):334-342.
54. de Winter R.F., van Hemert A.M., DeRijk R.H., Zwinderman K.H., Frankhuijzen-Sierevogel A.C., Wiegant V.M., et al. Anxious-retarded depression: relation with plasma vasopressin and cortisol. Neuropsychopharmacology 2003, 28(1):140-147.
55. Liebowitz M.R., Hollander E., Schneier F., Campeas R., Welkowitz L., Hatterer J., et al. Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatr Scand Suppl 1990, 360:29-34.
56. Shulman K.I., Herrmann N., Walker S.E. Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs 2013, 27(10):789-797.
57. Tatsumi M., Groshan K., Blakely R.D., Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997, 340(2-3):249-258.
58. Gillman P.K. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007, 151(6):737-748.
59. Wilson K., Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int J Geriatr Psychiatry 2004, 19(8):754-762.
60. Berken G.H., Weinstein D.O., Stern W.C. Weight gain. A side-effect of tricyclic antidepressants. J Affect Disord 1984, 7(2):133-138.
61. Reimherr F.W., Amsterdam J.D., Quitkin F.M., Rosenbaum J.F., Fava M., Zajecka J., et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term Fluoxetine treatment. Am J Psychiatry 1998, 155(9):1247-1253.
62. Mrazek D.A., Biernacka J.M., McAlpine D.E., Benitez J., Karpyak V.M., Williams M.D., et al. Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study. J Clin Psychopharmacol 2014, 34(3):313-317.
63. Sinyor M., Schaffer A., Levitt A. The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatry 2010, 55(3):126-135.
64. Howland R.H. Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 2: study outcomes. J Psychosoc Nurs Ment Health Serv 2008, 46(10):21-24.
65. Depping M.S., Wolf R.C., Nolte H.M., Palm E., Hirjak D., Thomann P.A. Electroconvulsive therapy in depression: insights from fMRI, PET and SPECT studies. Fortschr Neurol Psychiatr 2014 Sep, 82(9):511-522.
66. Rudorfer M.V., Henry M.E., Sackeim H.A. Electroconvulsive therapy. Psychiatry 2003, John Wiley & Sons Ltd., Chichester. 2nd ed. A. Tasman, J. Kay, J.A. Lieberman (Eds.).
67. Hasler G., van der Veen J.W., Tumonis T., Meyers N., Shen J., Drevets W.C. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2007, 64(2):193-200.
68. Anderson R.J., Frye M.A., Abulseoud O.A., Lee K.H., McGillivray J.A., Berk M., et al. Deep brain stimulation for treatment-resistant depression: efficacy, safety and mechanisms of action. Neurosci Biobehav Rev 2012, 36(8):1920-1933.
69. Moreines J.L., McClintock S.M., Holtzheimer P.E. Neuropsychologic effects of neuromodulation techniques for treatment-resistant depression: a review. Brain Stimul 2011, 4(1):17-27.
70. Romeas T., Morissette M.C., Mnie-Filali O., Piñeyro G., Boye S.M. Simultaneous anhedonia and exaggerated locomotor activation in an animal model of depression. Psychopharmacology (Berl) 2009, 205(2):293-303.
71. Song C., Leonard B.E. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 2005, 29:627-647.
72. Kelly J.P., Wrynn A.S., Leonard B.E. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 1997, 74(3):299-316.
73. Bao S., Fei J., Shen J., Gong S.J., Fang H., Husband A.J. Reserpine-induced model of stress suppresses mucosal immunity. Immunol Cell Biol 2006, 84(6):537-542.
74. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1997, 229(2):327-336.
75. Isingrini E., Camus V., Le Guisquet A.M., Pingaud M., Devers S., Belzung C. Association between repeated unpredictable chronic mild stress (UCMS) procedures with a high fat diet: a model of fluoxetine resistance in mice. PLoS One 2010, 5(4):e10404.
76. Belzung C. Innovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?. Neuropsychopharmacology 2014, 39(5):1041-1051.